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Abstract 
The substrate scope of fluorinase enzyme mediated transhalogenation reactions is extended. Substrate 
tolerance allows a peptide cargo to be tethered to a 5'-chloro-5'-deoxynucleoside substrate for 
transhalogenation by the enzyme to a 5'-fluoro-5'-deoxynucleoside. The reaction is successfully 
extended from that previously reported for a monomeric cyclic peptide (cRGD) to cargoes of 
dendritic scaffolds carrying two and four cyclic peptide motifs. The RGD peptide sequence is known 
to bind upregulated αVβ3 integrin motifs on the surface of cancer cells and it is demonstrated that the 
fluorinated products have a higher affinity to αVβ3 integrin than their monomeric counterparts. 
Extending the strategy to radiolabelling of the peptide cargoes by tagging the peptides with  
[18F]fluoride was only moderately successful due to the poor water solubility of these higher order 
peptide scaffolds although the strategy holds promise for peptide constructs with improved solubility.  
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1. Introduction 
The fluorinase enzyme (E.C. 2.5.1.63) was originally isolated1 from the soil bacterium Streptomyces 
cattleya and has recently been identified in a number of other bacterial species.2 The enzyme shows 
promise as a biocatalyst for the incorporation of fluorine-18 into [18F]-labelled PET radiotracers, and 
has the singular attribute that the C-F bond forming reaction is carried out under neutral aqueous 
conditions.3–6 The fluorinase catalyses the combination of fluoride ion and S-adenosyl-L-methionine 1 
(SAM) to generate 5'-fluoro-5'-deoxyadenosine 2 (FDA) and L-(S)-methionine 3 (L-Met) (Scheme 1 
A).1,7 We have recently demonstrated that the enzyme has a specificity tolerance at the 2-position of 
the adenine base.5 Replacement of hydrogen with an acetylene group at this position, as shown in 
Scheme 1 B, gave the modified substrate ClDEA 4 which was an efficient substrate for 
transhalogenation in the presence of Se-adenosyl-L-selenomethionine (SeSAM)7. This transformation 
was utilised to prepare [18F]FDEA [18F]-6 under ambient aqueous conditions. The pendant acetylene 
moiety was then efficiently reacted with an azido-cRGD (cyclic arginyl-glycinyl-aspartyl) peptide 
using the CuAAC (Cu-catalysed alkyne-azide cycloaddition) click reaction, to generate a [18F]-
radiolabelled cRGD construct.6  
 Scheme 1. A. The native reaction catalysed by the fluorinase enzyme. B. Fluorinase catalysed transhalogenation 
reactions with C-2 modified substrates. 
While two step strategies involving prosthetic groups remain widely used for radiolabelling of 
peptides and proteins with fluorine-18,8 it is attractive to consider the development of straightforward, 
“last step” radiolabelling protocols. Such protocols need to be relatively rapid due to the short half-life 
of fluorine-18 (t1/2 =109.7 min), and be conducted under conditions that preserve the structural and 
functional integrity of the biomolecule.9 The poor nucleophilicity of aqueous [18F]fluoride ion, the 
form most readily prepared on a cyclotron with an [18O]H2O target,10 often precludes direct labelling 
of biomolecules using a “last step” approach. To circumvent the limited reactivity of aqueous 
[18F]fluoride, fluoride sequestering strategies have been explored. For example boron,11 aluminium12 
and silicon13 based methods have been developed in an effort to achieve “last step” radiolabelling of 
peptides by bioconjugation approaches which secure these elements to the peptide in advance. The 
strategies have proven successful and these technologies are being further developed,14,15 but there are 
challenges as the conditions required to achieve fluoride ion sequestration require various 
combinations of low pH, organic solvents and heating. The fluorinase has the capacity to catalyse C-F 
bond formation at ambient temperature and near neutral pH. Within this context, we have previously 
demonstrated5 a fluorinase enzyme-based system for “last step” radiolabelling of a small cRGD 
peptide 7. The peptide was tethered to a 5'-chloro-5'-deoxynucleoside substrate through a PEG linker 
prior to enzymatic radiolabelling with [18F]fluoride, as shown in Scheme 1 B. This proved successful 
and the radiolabelled construct [18F]-8 was shown to be stable to defluorination in vivo (in a rat), and 
the cRGD moiety retained high affinity for αVβ3 integrins. In order to explore this approach further, 
we wished to examine whether the substrate scope at the C-2 position would extend to larger, more 
complex peptides. 
The search for high affinity ligands for biological receptors has led to the development of imaging 
agents based on multivalent antibody fragments16 or multivalent small peptides.17 Multimeric 
interactions play a key role in recognition events between biological ligands and receptors.18 Weak 
non-covalent interactions between monovalent ligands and individual receptors can be enhanced by 
attaching multiple ligands to a single scaffold.19,20 Incorporating the RGD (arginyl-glycinyl-aspartyl) 
tripeptide motif into cyclic pentapeptides gives cRGDs, a class of high affinity ligands for αVβ3 
integrin, a cell surface protein identified as a biomarker of angiogenesis and strongly associated with 
malignant tumours.21,22 Multimeric cRGD peptides are validated constructs employed for PET 
imaging using either fluorine-18 or heavy metal PET isotopes.19,23,24 Usually the cRGD peptide is 
conjugated to a metal chelating group for co-ordination to radiometals, often at the final step in the 
synthesis of such a tracer. Fewer fluorine-18-based multivalent radiotracers have been developed, as 
incorporation of fluorine-18 into such scaffolds often requires a multi-step, prosthetic group-based 
strategy.25–28 However, two multimeric cRGD-based radiotracers have been reported recently, 
synthesised using a “last step” radiofluorination protocol. These are the aluminium chelates, 
[18F]alfatide I14,29 and [18F]alfatide II15,30 which were prepared using a kit-like31 methodology and they 
have been evaluated in humans.14,15 In addition, the CuAAC reaction between an alkyne and an azide-
modified cRGD peptide has also proved useful for the assembly of multimeric cRGD peptides, which 
were subsequently labelled with radometals.32–35 
Herein, we report our initial results on “last step” fluorination of structurally complex multimeric 
cRGD peptides with the fluorinase enzyme. A primary objective at this stage was to establish if the 
fluorinase could tolerate higher molecular weight cargoes attached to the C-2 position of the adenine 
base. Although successful biotransformations could be achieved with fluoride, it became apparent that 
reduced solubility of higher molecular weight substrates proved challenging for efficient radiolabelled 
experiments, where the fluoride-18 concentrations are necessarily low.   
Results and Discussion 
1.1. Synthesis of di- and tetra-alkynes for a CuAAC reaction 
A multimeric peptide substrate for the fluorinase requires an enzyme recognition/reaction site 
attached to a linker to extend the peptide cargo away from the surface of the enzyme. In order to 
assemble such a substrate, we envisaged a strategy similar to that used for the synthesis of 5 and 7 
(Scheme 1 B).5 A Sonogashira coupling was identified for coupling a 2-iodonucleoside to an alkynyl-
PEG linker, which had been pre-functionalised with either a protected dialkyne or a protected 
tetraalkyne. Following deprotection to the free terminal alkynes, a multi-CuAAC reaction with an 
azide bearing cRGD peptide, similar to that reported by Liskamp et al.,34 should furnish multimeric 
cRGD substrates. The synthesis of the protected alkynes and halogenated 2-iodo-nucleosides is 
summarised in Scheme 2 and Scheme 3 respectively. 
 Scheme 2. Synthesis of protected aldehyde 11 and amine 14 for reductive amination to generate the desired alkynyl 
frameworks 15 and 16.  
The dendrimeric core was prepared by dialkylation of methyl 3,5-dihydroxybenzoate 9 with propargyl 
bromide (Scheme 2).34 The acetylenes of the newly installed propargylic ethers were then silylated to 
furnish ester 10. The ester 10 was then reduced to the corresponding benzylic alcohol and periodinane 
oxidation 36 generated aldehyde 11 which was used directly in a future reductive amination reactions 
without further purification. The linker was prepared by monoalkylation of tetraethylene glycol 12 
propargyl chloride. The free hydroxyl was converted to the corresponding tosyl ester and then 
nucleophilic displacement by azide gave the corresponding azido-PEG. Reduction under Staudinger 
conditions37 gave amine 14. With both aldehyde 11 and amine 14 in hand, attention turned to coupling 
the linker to the multimeric core. 
The reductive amination after condensation of amine 14 with aldehyde 1138 generated both the mono- 
and di- alkylated products 15 and 16. Separation of the two products by column chromatography gave 
the di-alkyne linker-core assembly 15 in 35% yield (based on aldehyde 11), while the terta-alkyne 
linker-core assembly 16 was formed in 21% yield (based on aldehyde 11). 
With these linker-core assemblies in hand, attention turned to the synthesis of the iodinated coupling 
partners. 2-Iodoadenosine 17,5 was treated with thionyl chloride in pyridine, followed by ammonia in 
aqueous methanol to furnish the 5'-chloro-5’-deoxy adenosine 18, as shown in Scheme 3.39 For the 
synthesis of the fluorinated nucleoside, 2-iodoadenosine 17 was protected as its 2',3'-acetonide 19 
before being fluorinated by the action of TsF and TBAF in refluxing THF. Deprotection to generate 
20 was achieved in good yield with catalytic anhydrous TsOH in refluxing MeOH.40  
 Scheme 3. Synthesis of halogenated 2-iodo coupling partners 18 and 20 for Sonogashira coupling. 
Sonogashira couplings41–43 of the halogenated 2-iodonucleosides 18 and 20 with acetylenes 15 and 16 
were now explored. 5'-Chloro-5'-deoxy-2-iodoadenosine 18 was added to an excess of either alkyne 
15 or 16 in dry, degassed DMF, in the presence of Pd(PPh3)2Cl2 (10 mol%), CuI, and triethylamine. 
TLC and LC-MS was used to monitoring the formation of coupled products 21 and 25.  
 
Scheme 4. Synthesis of pendant di- and tetra- acetylene cores attached to 5’-halo-5’deoxyadenosine motifs.   
Coupled di- alkyne 21 and tetra- 25 were subject to column chromatography before fluoride-based 
deprotection of the silyl groups using 3HF.Et3N in methanol. The products 22 and 26 were each 
passed through a plug of silica gel, then through a C18 reverse phase cartridge, before being purified 
by semi-preparative HPLC to give analytically pure samples of ClDEA-PEG-(C≡CH)2 22 and 
ClDEA-PEG-(C≡CH)4 26 for CuAAC reactions. Following a similar protocol, FDEA-PEG-(C≡CH)2 
24 and FDEA-PEG-(C≡CH)4 28 were prepared and purified by semi-preparative HPLC.  
It became a focus to ‘click’ the multimeric alkynes to the cRGD peptides in aqueous CuAAC 
reactions with c(RGDfK[N3]) 29 as illustrated in Scheme 5 A. The reactions were conducted with 
CuSO4.TBTA (TBTA = tris(benzyltriazolylmethyl)amine44) and sodium ascorbate as the catalyst, and 
were monitored by HPLC. The triazole products were trapped on a C18 cartridge, and eluted with 
MeCN/water mixture and purified by semi-preparative HPLC. This gave samples of ClDEA-PEG-
(RGD)2 30 (1.8 mg, 78% yield) and FDEA-PEG-(RGD)2 31 (0.67 mg, 27% yield), the integrity of 
which was supported by MALDI-TOF MS analyses (see Supplementary Information). The fluorinated 
analogue, FDEA-PEG-(RGD)2 31, was required as a standard for assessing affinity to targets. 
 
Scheme 5. A. Synthesis of ClDEA-PEG-(RGD)2 30 and FDEA-PEG-(RGD)2 31. B. Synthesis of ClDEA-PEG-
(RGD)4 32 and FDEA-PEG-(RGD)4 33. 
ClDEA-PEG-(C≡CH)4 26 was found to be poorly soluble in water and the CuAAC reaction with 
c(RGDfK[N3]) 29 (Scheme 5 B) was sluggish, but the use of 50:50 DMSO:water as a reaction solvent 
led to complete conversion within 70 minutes. The reaction product was trapped on a C18 cartridge, 
and was washed with water to remove residual DMSO, and then the product was eluted with 
MeCN:water mixtures. Purification by semi-preparative HPLC gave ClDEA-PEG-(RGD)4 32 (1.4 
mg, 70% yield), the integrity of which was confirmed by MALDI-TOF MS (see Supplementary 
Information). The tetra-acetylene, FDEA-PEG-(C≡CH)4 26 was similarly reacted in a mixture of 
DMSO:water, with c(RGDfK[N3]) 29. HPLC purification gave the desired reference compound 
FDEA-PEG-(RGD)4 33 (0.66 mg, 27% yield) with a m/z = 3412.6 ([M+H]+) as determined by 
MALDI-TOF MS (see Supplementary Information). 
1.2. Evaluation of multimeric RGDs as substrates for the fluorinase 
With the multieric cRGD fluorinase substrates in hand, enzyme catalysed transhalogenation reactions 
were explored. For example ClDEA-PEG-(RGD)2 30 (40 µM) was added to a mixture of L-SeMet (75 
µM) and potassium fluoride (50 mM) in a 1mL volume to explore the transformation illustrated in 
Figure 1 A. The reaction was initiated by addition of the fluorinase (1 mg.mL−1). Aliquots of the 
reaction were removed for HPLC assay over a 4 h period in order to assess conversion. The HPLC 
traces in Figure 1 B show the time-dependent appearance of the product at tR = 8.2 min, a peak which 
was identified as FDEA-PEG-(RGD)2 31 by LC-MS comparison with the synthetic reference 
previously prepared. The mass spectra of the HPLC peaks corresponding to the multimeric 5'-chloro 
substrates and 5'-fluoro products are shown in Figure 1C and D respectively. The peaks for the 
product contain multiply charged ions of 31 ([M+2H]2+, [M+3H]3+, and [M+4H]4+ respectively), 
confirming its identity as FDEA-PEG-(RGD)2 31. 
 
Figure 1. A. Fluorinase catalysed transhalogenation of ClDEA-PEG-(RGD)2 30 to FDEA-PEG-(RGD)2 31. B. HPLC 
time course (220 nm) of incubation of ClDEA-PEG-(RGD)2 30, blue, (tR = 12.2 min) with the fluorinase, 
showing samples taken every 0.5 h over 4 h. A new peak was evident at tR = 8.2 min, red, identified as 
FDEA-PEG-(RGD)2 31. Summed mass spectrum (m/z = 400–1000) of the LC-MS peaks corresponding to the 
tetrameric species from a sample taken at C. t = 0 h, showing peaks corresponding to multiply charged 
species of ClDEA-PEG-(RGD)2 30, and at D. t = 4 h, showing peaks corresponding to multiply charged 
species of FDEA-PEG-(RGD)2 31. 
A series of control experiments, where the reaction was conducted in the absence of either enzyme or 
L-SeMet, did not result in any conversion of 30 to 31, confirming an enzyme catalysed process. In the 
absence of fluoride, the consumption of 30 was observed, however, no fluorinated product was 
produced. This result is consistent with the generation of a SeSAM intermediate, which cannot be 
converted to product 31 in the absence of fluoride. 
A similar analysis was conducted for the enzymatic reaction with ClDEA-PEG-(RGD)4 32, as 
illustrated in Figure 2 A. ClDEA-PEG-(RGD)4 32 (20 µM) was added to a mixture of 
L-SeMet (75 µM) and potassium fluoride (50 mM), in a total volume of 1 mL. The reaction was 
initiated by the addition of the fluorinase (1 mg.mL−1) and monitored over 4 h. The resultant HPLC 
profile (Figure 2 B) indicated that 32 was consumed, while a new peak, at tR = 9.2 min, steadily 
increased throughout the assay. The retention time of this new peak was identical to that of synthetic 
FDEA-PEG-(RGD)4 33, and its identity was further confirmed by LC-MS. 
 
Figure 2. A. Fluorinase catalysed transhalogenation of ClDEA-PEG-(RGD)4 32 to FDEA-PEG-(RGD)4 33. B. HPLC 
time course (220 nm) of incubation of ClDEA-PEG-(RGD)4 32, green, (tR = 12.4 min) with the fluorinase, 
showing samples taken every 0.5 h over 4 h. A new peak was evident at tR = 9.2 min, yellow, identified as 
FDEA-PEG-(RGD)4 33. Summed mass spectrum (m/z = 600–1000) of the LC-MS peak corresponding to the 
tetrameric species of samples taken at B. t = 0 h, showing peaks corresponding to multiply charged species of 
ClDEA-PEG-(RGD)4 32 and at C. t = 16 h, showing peaks corresponding to multiply charged species of 
FDEA-PEG-(RGD)4 22. Identical fragmentation peaks (denoted with an asterisk (*)) appear in both spectra, 
thought to arise from fragmentation of the adenine (C-2)–(C≡CR) bond. 
Mass spectra the tetrameric substrate and product are shown in Figure 2 C and D respectively. In the 
sample analysed at t = 0 h (Figure 2 C), peaks corresponding to multiply charged species of ClDEA-
PEG-(RGD)4 32 are observed at m/z = 858.9 ([M+4H]4+) and 687.2 ([M+5H]5+). In the sample 
analysed after an extended 16 h reaction (Figure 2 D), peaks at m/z = 854.8 ([M+4H]4+) and 683.8 
([M+5H]5+) are clearly observed. The presence of these ions is consistent with the formation of 
FDEA-PEG-(RGD)4 33 as the product of enzymatic transhalogenation.  
Tolerance of the fluorinase to these large multimeric peptides suggests that the C-2 position of a 
chlorinated nucleoside represents a site for the attachment of a diverse range of peptide cargos for use 
in enzymatic fluorination. The constructs explored here consist of 10 and 20 amino acids, and they 
were efficiently fluorinated under neutral aqueous conditions. With the knowledge that the multimeric 
constructs were suitable substrates for fluorinase catalysed transhalogenation, it was of interest to 
evaluate the effect the multiple RGD motifs on binding affinity to αVβ3 integrin. 
1.3. Binding affinities of RGD multimers to immobilised αVβ3 integrin. 
The binding affinities of the fluorinated multimers 31 and 33 to αVβ3 integrin were determined by 
their ability to displace a biotin-labelled cRGD peptide from immobilised αVβ3 integrin in an ELISA 
assay.45 The data are shown in Table 1 including the IC50 values of some reference peptides.5,6 The 
ELISA data indicate that for this series the multimers have a progressively higher integrin affinity 
(lower IC50) as the number of cRGD ligands increases eg. monomeric 8 (IC50 = 74 nM), dimeric 31 
(IC50 = 60 nM) and tetrameric 33 (IC50 = 24 nM). The IC50 values measured for the multimeric 
constructs are also lower than the parent azido-peptide 29 (IC50 = 90 nM) and the multimeric cRGD 
compounds have significantly lower IC50 values compared with reference compounds containing 
linear RGD-containing peptides. 
Table 1. IC50 values of selected RGD-containing peptides measured as the ability to compete with c(RGDfK[PEG-
PEG-biotin]) for binding to immobilised αVβ3 integrin. Results are the average ± standard error (s.e.) from 
three independent experiments, each performed in triplicate. Q is the normalised affinity of the peptides, 
referenced to GRGDSPK. aAffinities for these constructs were previously reported, and were measured using 
an identical assay. 
Compound IC50 ± s.e /nM  Q 
RGDa 8560 ± 2240 4.019 
GRGDSPKa 2130 ± 410 1.000 
c(RGDfK[N3]) 29a 90 ± 10 0.042 
FDEA-cRGDa 330 ± 30 0.155 
FDEA-TEG-cRGD 8a 74 ± 16 0.033 
FDEA-PEG-(cRGD)2 31 60 ± 13 0.027 
FDEA-PEG-(cRGD)4 33 24 ± 18 0.011 
 
The increase in going from one to two cRGD motifs resulted in a marginal increase in binding affinity 
however progression to a tetramer showed a significant decrease in IC50 and gave a compound with 
the highest affinity of those tested. The linker between the two or four cRGD units is not so extended 
and steric constraints will likely prevent simultaneous multivalent binding of cRGDs to more than one 
surface site. Instead the increased affinity is most likely due to an increased effective molarity at the 
surface.46 Some multimeric constructs reported in the literature have IC50 values in the 1–100 nM 
range,24 similar to this study although a direct comparison of different assays and dissimilar peptide 
motifs make comparison difficult.  
1.4. Enzymatic radiolabelling of multimers with fluorine-18 
The ability of the fluorinase to employ these large peptide assemblies of 10 or 20 amino acids as 
substrates opened up prospects of labelling these peptides with [18F]fluoride for PET. Radiolabelling 
trials of ClDEA-PEG-(RGD)2 30 (0.04 mM) was initially investigated using similar reaction 
conditions to the assays described with [19F]fluoride, but with an aqueous [18F]fluoride solution 
generated on the cyclotron. The enzyme concentration was increased from 1 mg.mL−1 (29 µM) to 10 
mg.mL−1 (290 µM), as it had previously been shown that high enzyme concentrations improves 
conversions in radiolabelling experiments.47  Notably [18F]fluoride ion concentrations are necessarily 
very low in the pico-molar range. Radiochemical incorporations (RCI) were found to be low under 
these conditions, and only traces of the product, [18F]FDEA-PEG-(RGD)2 [18F]-31 were observed by 
radio-HPLC. Optimisation trials were carried out with ClDA 4 to [18F]FDA [18F]-2 as a substrate, and 
the data suggest that an important factor for improving radiochemical incorporations is substrate 
concentration. A RCI of greater than 90% was observed when ClDA 4 was incubated at a 
concentration of 0.6 mM, compared with a 10% RCI at 0.04 mM (see Supplementary Information). 
By contrast, ClDEA-PEG-(RGD)2 30 and ClDEA-PEG-(RGD)4 32 were found to be poorly soluble in 
water, and concentrations of 0.6 mM were not achievable in buffer. The upper concentration limit for 
the peptides was found to be ~0.3 mM. ClDEA-PEG-(RGD)2 30 and ClDEA-PEG-(RGD)4 32 were 
incubated in separate experiments with L-SeMet (0.08 mM) and [18F]fluoride in water (138 µL–160 
µL, 15.2–35.4 MBq). Some precipitation of the substrate was observed upon addition of aqueous 
[18F]fluoride. The reaction mixtures were incubated at 37 °C for 30 minutes, and then the enzyme was 
heat denatured and the mixture centrifuged. A sample of the clarified supernatant from each reaction 
was analysed by HPLC, and the resultant HPLC radio-chromatograms are shown in Figure 3. 
 Figure 3. A. Reaction scheme and resultant isocratic HPLC radioactivity trace of experiment where ClDEA-PEG-
(RGD)2 30 (0.3 mM) freeze dried with the fluorinase (20 mg.mL−1) prior to reaction. [18F]FDEA-PEG-
(RGD)2 [18F]-31 was observed at tR = 13.7 min, showing 10% RCI. B. Reaction scheme and resultant gradient 
HPLC radioactivity trace of experiment where ClDEA-PEG-(RGD)4 32 (0.3 mM) freeze dried with the 
fluorinase (20 mg.mL−1) prior to reaction. [18F]FDEA-PEG-(RGD)4 [18F]-33 was observed at tR = 10.1 min, 
showing 5% RCI. An additional peak was also observed at tR = 5.2 min, identified as [18F]FDA [18F]-2, 
produced due to the presence of residual SAM 1 co-purified with the fluorinase.48 The peak is also present for 
ClDEA-PEG-(RGD)2 30 labelling experiments, but is not observed in A due to the HPLC conditions utilised 
(see Supplementary Information for further discussion). 
Radio-HPLC of the two reaction mixtures (Figure 3 A and B) revealed the presence of the respective 
[18F]-products, along with broad peak (tR = 2.2 min), identified as [18F]fluoride.49 The peak at tR = 
13.7 min in Figure 3 A was identified as [18F]-31 by spiking and comparison of the retention time to 
that of a [19F]-reference sample. Similarly the peak at tR = 10.1 min in Figure 3 B was identified as 
[18F]-33 relative to a [19F]-reference. [18F]-FDA [18F]-2 was also observed in this experiment, which 
must arise as a consequence of low levels of L-AdoMet (SAM) bound to the enzyme and residual 
from the purification process. This outcome only arose in the reactions of low conversion. Reactions 
were also conducted with the addition of DMSO 1% (v/v) as a co-solvent, however this did not 
improve the radiochemical conversions and extending the reaction time or increasing the 
concentration of L-SeMet had no significant effect.  Therefore despite the efficient conversions 
observed in the “cold” experiments at high [19F]fluoride ion concentrations, low [18F]fluoride 
concentrations require to be compensated for by high substrate concentrations, and this limited the 
efficiency of the radiolabelled experiments.   
2. Conclusions 
Enzymatic transhalogenations using the fluorinase was explored with relatively complex di- and tetra 
cRGD constructs. This exploited the previously identified substrate tolerance at C-2 of adenine base 
in the substrate motif. The multimeric assemblies, ClDEA-PEG-(RGD)2 30 and ClDEA-PEG-(RGD)4 
32, were assessed as fluorinase substrates and both were found to undergo efficient enzyme-catalysed 
transhalogenations. The multimers also showed higher affinities to immobilised αVβ3 integrins, which 
opened up the prospect of using them as cancer imaging agents in [18F]-radiolabelled form. This 
proved only partially successful due to the relatively poor solubility of the multimeric constructs and 
low [18F]-fluoride concentrations. It follows that the development of this approach to larger peptides 
or proteins will depend on using more highly soluble peptide substrates in buffer. The peptides used 
here are ‘click’ derived with low solubility, however the approach should prove more useful with 
natural peptides and antibodies which have evolved high water solubility.  
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